Papillon Therapeutics Receives Rare Pediatric Disease Designation from the U.S. Food and Drug Administration for PPL-001 for the Treatment of Friedreich’s Ataxia
Industry News
Blog|Oct 14 2024
2024 rideATAXIA Hometown Twin Cities, MN
Events
News|Oct 8 2024
PTC Therapeutics Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program
Industry News
Blog|Oct 4 2024
Meet the Community 2: A Closer Look — Alijana Shakya
Community
Blog|Sep 30 2024
2024 Fuzzy Buzzy Recap
Events
Blog|Sep 23 2024
Meet the Community 2: A Closer Look – Alex Fielding
Community
News|Sep 20 2024
Congressional Resolution Passes to Designate September 25 as “National Ataxia Awareness Day”
Advocacy
News|Sep 17 2024
Papillon Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for PPL-001 for the Treatment of Friedreich’s Ataxia
Industry News
Blog|Sep 16 2024
Meet the Community: Allison Rice
Community
News|Sep 11 2024
Stealth BioTherapeutics Awarded Grant from Friedreich’s Ataxia Research Alliance and FARA Ireland to Develop Investigational Mitochondrial Therapeutic SBT-589 for Friedreich’s Ataxia